Abstract:Background: Stapokibart has been approved for the treatment of adults with atopic dermatitis (AD) in China.
Objective: To report long-term efficacy of stapokibart in patients with moderate-to-severe AD.
Methods: This post hoc analysis included 237 adult patients from a phase 3 trial (NCT05265923) who received stapokibart 300 mg (loading dose, 600 mg) every 2 weeks during the 16-week double-blind period and continued with the same dose of stapokibart in the subsequent 36-week maintenance period.
Results: At week 20, 100% and 92.2% of patients who achieved coprimary endpoints (≥75% improvement in Eczema Area and Severity Index [EASI-75] and Investigator’s Global Assessment [IGA] 0/1 response) at week 16 retained their EASI-75 and IGA 0/1 response, respectively. At week 52, these figures reached 99.0% and 87.0%, respectively. Among those who had not achieved EASI-75 or IGA 0/1 at week 16, 65.4% achieved EASI-75 and 18.1% achieved IGA 0/1 at week 20, and reached 86.8% and 50.0% at week 52, respectively. The patient-reported outcomes also improved sustainedly.
Conclusions: Long-term stapokibart treatment induced sustained clinical improvements in adult patients with moderate-to-severe AD, regardless of their initial response to 16-week treatments.
Get full access to this article
View all access options for this article.
References
1.
StänderS. Atopic dermatitis. N Engl J Med. 2021; 384(12):1136–1143.
2.
BeckLA, DeleuranM, BissonnetteR, et al.Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022; 23(3):393–408.
3.
BlauveltA, LangleyRG, LacourJP, et al.Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022; 87(4):815–824.
4.
DavisDMR, DruckerAM, AlikhanA, et al.Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024; 90(2):e43–e56.
5.
SilverbergJI, Guttman-YasskyE, ThaçiD, et al.; ADvocate1 and ADvocate2 Investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023; 388(12):1080–1091.
6.
GargiuloL, IbbaL, MalagoliP, et al.Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: An italian delphi consensus. Dermatol Ther (Heidelb). 2024; 14(4):919–932.
7.
HaagC, AlexisA, AokiV, et al.A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council. Br J Dermatol. 2024; 192(1):135–143.
8.
LicataG, TancrediV, PezzoloE, et al.Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series. Acad Dermatol Venereol. 2023; 37(8).
9.
ZhaoY, ZhangL, ZhangJ, CM310AD005 Study Investigators. Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2024; 91(5):984–986.
10.
ZhaoY, ZhangL, WuL, et al.Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. Allergy. 2024.
11.
ShenS, YanB, WangM, et al.Anti-IL-4Rα monoclonal antibody (CM310) in patients with chronic rhinosinusitis with nasal polyps (CROWNS-2): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Asia Pac Allergy. 2024; 14(3):118–123.
12.
WormM, SimpsonEL, ThaçiD, et al.Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020; 156(2):131–143.
13.
BlauveltA, ThyssenJP, Guttman-YasskyE, et al.Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023; 188(6):740–748.
14.
BlauveltA, SilverbergJI, LyndeCW, et al.Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022; 86(1):104–112.
15.
WeisshaarE, BentzP, ApfelbacherC, et al.; TREATgermany study group. Itching in atopic dermatitis: Patient- and physician-reported outcomes in the german atopic dermatitis registry TREATgermany. Acta Derm Venereol. 2023; 103:adv00854.
16.
ArmstrongA, BlauveltA, SimpsonEL, et al.Continued treatment with dupilumab is associated with improved efficacy in adults with moderate-to-severe atopic dermatitis not achieving optimal responses with short-term treatment. Dermatol Ther (Heidelb). 2022; 12(1):195–202.
17.
LiuW, ZhaoY, HeY, et al.Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation. iScience. 2024; 27(9):110721.
18.
SilverbergJI, GooderhamM, KatohN, et al.Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024; 38(11):2139–2148.
